Affimed update #2
AFM24+atezolizumab in EGFR+ solid tumors
Following our update #1 last week, Affimed jumped yesterday after reporting unexpected activity of AFM24+atezolizumab in EGFR-positive solid tumors.
The initial results from the Phase 1 dose escalation study showed that among 3 patients in the lowest dose cohort 1 (160mg), there was 1 ongoing partial response in a patient with gastric cancer and skin met…